$DYAI
Dyadic International Inc

2020 Q4 Form 10-Q Financial Statement

#000121380920000036 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $350.0K $416.4K $454.5K
YoY Change -18.6% -8.39% 72.84%
Cost Of Revenue $260.0K $266.9K $384.8K
YoY Change -38.1% -30.63% 58.09%
Gross Profit $90.00K $149.4K $69.70K
YoY Change 800.0% 114.38% 256.47%
Gross Profit Margin 25.71% 35.89% 15.34%
Selling, General & Admin $1.310M $1.640M $1.060M
YoY Change 12.93% 54.72% 3.92%
% of Gross Profit 1455.56% 1097.49% 1520.72%
Research & Development $1.010M $986.1K $841.3K
YoY Change 29.49% 17.2% 76.52%
% of Gross Profit 1122.22% 659.87% 1207.02%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.310M $986.1K $841.3K
YoY Change 18.46% 17.2% 76.52%
Operating Profit -$2.220M -$2.576M -$1.943M
YoY Change 14.43% 32.57% 9.11%
Interest Expense $300.0K $76.81K $245.0K
YoY Change 42.86% -68.65% 1.4%
% of Operating Profit
Other Income/Expense, Net $76.81K
YoY Change
Pretax Income -$1.930M -$2.500M -$1.700M
YoY Change 11.56% 47.06% 10.39%
Income Tax $30.00K $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.960M -$2.499M -$1.698M
YoY Change 12.64% 47.17% 10.32%
Net Earnings / Revenue -560.0% -600.32% -373.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$71.30K -$90.98K -$62.55K
COMMON SHARES
Basic Shares Outstanding 27.48M shares 27.48M shares 27.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.09M $30.41M $35.46M
YoY Change -14.99% -14.24% -16.6%
Cash & Equivalents $20.64M $21.86M $4.662M
Short-Term Investments $8.460M $8.540M $30.79M
Other Short-Term Assets $280.0K $420.0K $80.00K
YoY Change 180.0% 425.0% -87.88%
Inventory
Prepaid Expenses
Receivables $294.2K $806.8K $418.9K
Other Receivables $120.0K $100.0K $500.0K
Total Short-Term Assets $29.78M $31.74M $36.46M
YoY Change -16.44% -12.94% -16.56%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $280.0K $0.00 $1.510M
YoY Change -81.46% -100.0%
Other Assets $6.225K $5.558K $50.23K
YoY Change -87.87% -88.94% 0.46%
Total Long-Term Assets $290.9K $5.558K $2.065M
YoY Change -83.96% -99.73% 3341.67%
TOTAL ASSETS
Total Short-Term Assets $29.78M $31.74M $36.46M
Total Long-Term Assets $290.9K $5.558K $2.065M
Total Assets $30.07M $31.75M $38.52M
YoY Change -19.71% -17.59% -11.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.013M $976.8K $713.4K
YoY Change 7.39% 36.92% 32.11%
Accrued Expenses $489.8K $620.6K $470.1K
YoY Change -13.47% 32.02% 95.88%
Deferred Revenue $123.0K $153.9K $93.28K
YoY Change 56.42% 64.95%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.626M $1.751M $1.277M
YoY Change 2.38% 37.16% 52.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.626M $1.751M $1.277M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.626M $1.750M $1.280M
YoY Change 2.26% 36.72% 52.38%
SHAREHOLDERS EQUITY
Retained Earnings -$50.68M -$48.72M -$39.61M
YoY Change 22.55% 22.98%
Common Stock $39.75K $39.74K $39.47K
YoY Change 0.34% 0.68%
Preferred Stock
YoY Change
Treasury Stock (at cost) $18.93M $18.90M $18.90M
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $28.45M $29.99M $37.24M
YoY Change
Total Liabilities & Shareholders Equity $30.07M $31.75M $38.52M
YoY Change -19.71% -17.59% -11.95%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$1.960M -$2.499M -$1.698M
YoY Change 12.64% 47.17% 10.32%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.280M -$1.390M -$1.540M
YoY Change -8.57% -9.74% 92.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $40.00K $11.45M $1.270M
YoY Change -97.01% 801.57% 3.25%
Cash From Investing Activities $40.00K $11.45M $1.270M
YoY Change -97.01% 801.57% 3.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K 0.000 180.0K
YoY Change -86.36% -100.0% -109.33%
NET CHANGE
Cash From Operating Activities -1.280M -1.390M -1.540M
Cash From Investing Activities 40.00K 11.45M 1.270M
Cash From Financing Activities 30.00K 0.000 180.0K
Net Change In Cash -1.210M 10.06M -90.00K
YoY Change -856.25% -11277.78% -94.0%
FREE CASH FLOW
Cash From Operating Activities -$1.280M -$1.390M -$1.540M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001213809
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ServiceMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ServiceMember
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21862581 USD
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 404
CY2017Q2 dyai Collaborative Arrangement Duration Of Agreement
CollaborativeArrangementDurationOfAgreement
P2Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55264
dei Entity Registrant Name
EntityRegistrantName
DYADIC INTERNATIONAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0486747
dei Entity Address Address Line1
EntityAddressAddressLine1
140 Intracoastal Pointe Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Jupiter
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33477
dei City Area Code
CityAreaCode
561
dei Local Phone Number
LocalPhoneNumber
743-8333
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4823544 USD
CY2020Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8544815 USD
CY2020Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0 USD
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
250308 USD
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
DYAI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27482157 shares
CY2019Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
29399146 USD
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
106405 USD
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
329711 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
806847 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
558530 USD
CY2020Q3 us-gaap Assets
Assets
31745704 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
419498 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
277999 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
31740146 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
35639238 USD
CY2020Q3 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2019Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
1511636 USD
CY2020Q3 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0 USD
CY2019Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
250308 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5558 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
51314 USD
CY2019Q4 us-gaap Assets
Assets
37452496 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
976762 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
943378 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
620633 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
566003 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
153855 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
78644 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1751250 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1588025 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
454507 USD
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39735659 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39612659 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27482157 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27359157 shares
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
39736 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
39613 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
97600771 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96105851 USD
CY2020Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502 shares
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1256004 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48716138 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41351078 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29994454 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
35864471 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31745704 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37452496 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
416361 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1247908 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
266929 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
384803 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1169351 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1034934 USD
CY2020Q3 dyai Provision For Contract Losses
ProvisionForContractLosses
112433 USD
CY2019Q3 dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
187388 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
986054 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
841343 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2857670 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2351953 USD
CY2020Q3 dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
0 USD
CY2019Q3 dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
101849 USD
dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
0 USD
dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
827632 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1643493 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1056196 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4772117 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4354941 USD
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
16240 USD
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-13727 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-26317 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-24693 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
2992669 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
2397918 USD
us-gaap Costs And Expenses
CostsAndExpenses
9012843 USD
us-gaap Costs And Expenses
CostsAndExpenses
8594153 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2576308 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1943411 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7756839 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7346245 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
76809 USD
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
245027 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
391779 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
777711 USD
CY2020Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2499499 USD
CY2019Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-1698384 USD
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-7365060 USD
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-6568534 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2499499 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1698384 USD
us-gaap Net Income Loss
NetIncomeLoss
-7365060 USD
us-gaap Net Income Loss
NetIncomeLoss
-6569434 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27482157 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27181003 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27467051 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26909205 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
35864471 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1264233 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
230810 USD
us-gaap Net Income Loss
NetIncomeLoss
-7365060 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29994454 USD
us-gaap Net Income Loss
NetIncomeLoss
-7365060 USD
us-gaap Net Income Loss
NetIncomeLoss
-6569434 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1264233 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1034346 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
282123 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
141362 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26317 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-24693 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-223306 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-58800 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
141698 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
110807 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-500616 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-497460 USD
dyai Increase Decreasein Prepaid Researchand Development
IncreaseDecreaseinPrepaidResearchandDevelopment
0 USD
dyai Increase Decreasein Prepaid Researchand Development
IncreaseDecreaseinPrepaidResearchandDevelopment
-253446 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
141550 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
164590 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-61651 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
429955 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
50745 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
70541 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
75211 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-47726 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5287408 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4381954 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
14677156 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
37585548 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
36761000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
43953000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22083844 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6367452 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
230810 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
328590 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
230810 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
328590 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11791 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-38075 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17039037 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2276013 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4823544 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2386314 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21862581 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4662327 USD
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
500616 USD
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
506866 USD
dyai Number Of Research Organizations
NumberOfResearchOrganizations
2 numberOfResearchOrganization
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 numberOfSegment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations and Credit RiskThe Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
806847 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
558530 USD
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
315261 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
173890 USD
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
103809 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
101221 USD
CY2020Q3 us-gaap Prepaid Taxes
PrepaidTaxes
428 USD
CY2019Q4 us-gaap Prepaid Taxes
PrepaidTaxes
2888 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
419498 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
277999 USD
CY2020Q3 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
727470 USD
CY2019Q4 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
766001 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
181342 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
26994 USD
CY2020Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
67950 USD
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
150383 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
976762 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
943378 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
396567 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
474388 USD
CY2020Q3 dyai Accrued Researchand Developmentin Process Current
AccruedResearchandDevelopmentinProcessCurrent
176791 USD
CY2019Q4 dyai Accrued Researchand Developmentin Process Current
AccruedResearchandDevelopmentinProcessCurrent
69795 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47275 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21820 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
620633 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
566003 USD
CY2020Q3 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
846564 USD
CY2019Q3 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
730190 USD
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
2431200 USD
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
1974176 USD
CY2020Q3 dyai Research And Development Expense Contracted Services Related Party
ResearchAndDevelopmentExpenseContractedServicesRelatedParty
0 USD
CY2019Q3 dyai Research And Development Expense Contracted Services Related Party
ResearchAndDevelopmentExpenseContractedServicesRelatedParty
101849 USD
dyai Research And Development Expense Contracted Services Related Party
ResearchAndDevelopmentExpenseContractedServicesRelatedParty
0 USD
dyai Research And Development Expense Contracted Services Related Party
ResearchAndDevelopmentExpenseContractedServicesRelatedParty
827632 USD
CY2020Q3 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
131553 USD
CY2019Q3 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
95269 USD
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
394706 USD
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
312321 USD
CY2020Q3 dyai Research And Development Expense Facilities Overheadand Other
ResearchAndDevelopmentExpenseFacilitiesOverheadandOther
7937 USD
CY2019Q3 dyai Research And Development Expense Facilities Overheadand Other
ResearchAndDevelopmentExpenseFacilitiesOverheadandOther
15884 USD
dyai Research And Development Expense Facilities Overheadand Other
ResearchAndDevelopmentExpenseFacilitiesOverheadandOther
31764 USD
dyai Research And Development Expense Facilities Overheadand Other
ResearchAndDevelopmentExpenseFacilitiesOverheadandOther
65456 USD
CY2020Q3 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
986054 USD
CY2019Q3 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
943192 USD
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
2857670 USD
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
3179585 USD
CY2020Q3 dyai Income Tax Expense Benefit Valuation Allowance Reversal
IncomeTaxExpenseBenefitValuationAllowanceReversal
1001233 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9400000 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
7200000 USD
CY2019Q4 dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1
CY2020Q3 dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4650390 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4650390 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4006390 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4006390 shares
CY2020Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21862581 USD
CY2020Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21862581 USD
CY2020Q3 us-gaap Investments And Cash
InvestmentsAndCash
30467696 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
60300 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q3 dyai Investmentsand Cash Amortized Cost
InvestmentsandCashAmortizedCost
30407396 USD
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4823544 USD
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4823544 USD
CY2019Q4 dyai Debt Securities Heldtomaturity Accumulated Unrecognized Loss Noncurrent
DebtSecuritiesHeldtomaturityAccumulatedUnrecognizedLossNoncurrent
0 USD
CY2019Q4 us-gaap Investments And Cash
InvestmentsAndCash
35738787 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22452 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17991 USD
CY2019Q4 dyai Investmentsand Cash Amortized Cost
InvestmentsandCashAmortizedCost
35734326 USD
CY2017Q2 dyai Collaborative Arrangement Paymentfor Researchand Development Agreement
CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
1100000 USD
CY2017Q2 dyai Collaborative Arrangement Paymentfor Researchand Development Agreement
CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
1000000 EUR
CY2020Q3 dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
0 USD
CY2019Q3 dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
100000 USD
dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
0 USD
dyai Researchand Development Expense Related Party
ResearchandDevelopmentExpenseRelatedParty
800000 USD
CY2020Q3 dyai Revenue From Collaborative Arrangement Recognized
RevenueFromCollaborativeArrangementRecognized
70000 USD
dyai Revenue From Collaborative Arrangement Recognized
RevenueFromCollaborativeArrangementRecognized
244000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4650390 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3860390 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3860390 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.76
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13287932 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
913000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.24
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
123000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M12D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4650390 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23870114 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3292794 shares
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
19067568 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
123000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.62
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
436613 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400681 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
144180 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1264233 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1034346 USD
dyai Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercisesin Period Common Stock Issued
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued
123000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
dyai Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercisesin Period Common Stock Issued
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodCommonStockIssued
499671 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
35864471 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426939 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2214139 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
34252271 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
309563 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2175258 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
40585474 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55743 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2651422 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
32093205 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
400680 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
68 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2499499 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29994454 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
42451169 USD
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
149180 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
580603 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2695792 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
38619465 USD
CY2019Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
179410 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
144180 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1698384 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
37244671 USD
CY2020Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502 shares
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502 shares
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD

Files In Submission

Name View Source Status
0001213809-20-000036-index-headers.html Edgar Link pending
0001213809-20-000036-index.html Edgar Link pending
0001213809-20-000036.txt Edgar Link pending
0001213809-20-000036-xbrl.zip Edgar Link pending
dyai-20200930.htm Edgar Link pending
dyai-20200930.xsd Edgar Link pending
dyai-20200930_cal.xml Edgar Link unprocessable
dyai-20200930_def.xml Edgar Link unprocessable
dyai-20200930_g1.jpg Edgar Link pending
dyai-20200930_htm.xml Edgar Link completed
dyai-20200930_lab.xml Edgar Link unprocessable
dyai-20200930_pre.xml Edgar Link unprocessable
exhibit311certificatio.htm Edgar Link pending
exhibit312certificatio.htm Edgar Link pending
exhibit321sec1350certi.htm Edgar Link pending
exhibit322sec1350certi.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending